West Nile virus: Biology, transmission, and human infection

Clinical Microbiology Reviews

Volumn 25, Issue 4, 2012, Pages 635-648

  Colpitts, Tonya M ^a   Conway, Michael J ^a   Montgomery, Ruth R ^a   Fikrig, Erol ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANPEP PROTEIN; CHEMOKINE RECEPTOR CCR5; DNA VACCINE; IMMUNOGLOBULIN M; INACTIVATED VIRUS VACCINE; INTERFERON REGULATORY FACTOR 3; LIVE VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E16; MX1 PROTEIN; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5; NUCLEOTIDYLTRANSFERASE; OASL PROTEIN; OLIGOADENYLATE SYNTHETASE 1B; RECOMBINANT ANTIBODY; RECOMBINANT VACCINE; RFC1 PROTEIN; SODIUM CHANNEL NAV1.1; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VECTOR; WEST NILE VACCINE;

AEDES; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE TRANSMISSION; DRUG PENETRATION; FLAVIVIRUS INFECTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOTHERAPY; INFECTION SENSITIVITY; LIFE CYCLE; NONHUMAN; NUCLEIC ACID ANALYSIS; PALLIATIVE THERAPY; PASSIVE IMMUNIZATION; RNA INTERFERENCE; SALIVA; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION; VIRUS CELL INTERACTION; VIRUS ENCEPHALITIS; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

ANIMALS; HOST-PATHOGEN INTERACTIONS; HUMANS; WEST NILE FEVER; WEST NILE VIRUS;

WEST NILE VIRUS;

EID: 84867167130     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00045-12     Document Type: Article

References (240)

1. Ader DB, et al. 2004. Modulation of dengue virus infection of dendritic cells by Aedes aegypti saliva. Viral Immunol. 17:252-265.
2. Anderson JF, Andreadis TG, Main AJ, Ferrandino FJ, Vossbrinck CR. 2006. West Nile virus from female and male mosquitoes (Diptera: Culicidae) in subterranean, ground, and canopy habitats in Connecticut. J. Med. Entomol. 43:1010-1019.
3. Anderson JF, et al. 1999. Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut. Science 286:2331-2333.
4. Andreadis TG, Anderson JF, Vossbrinck CR, Main AJ. 2004. Epidemiology of West Nile virus in Connecticut: a five-year analysis of mosquito data 1999-2003. Vector Borne Zoonotic Dis. 4:360-378.
5. Appler KK, et al. 2010. Persistence of West Nile virus in the central nervous system and periphery of mice. PLoS One 5:e10649. doi:10.1371/ journal.pone.0010649.
6. Arjona A, et al. 2007. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J. Clin. Invest. 117:3059-3066.
7. Arjona A, Wang P, Montgomery RR, Fikrig E. 2011. Innate immune control of West Nile virus infection. Cell. Microbiol. 13:1648-1658.
8. Arnold SJ, Osvath SR, Hall RA, King NJ, Sedger LM. 2004. Regulation of antigen processing and presentation molecules in West Nile virusinfected human skin fibroblasts. Virology 324:286-296.
9. Atkinson MP, et al. 2007. Analyzing the control of mosquito-borne diseases by a dominant lethal genetic system. Proc. Natl. Acad. Sci. U. S. A. 104:9540-9545.
10. Bai F, et al. 2009. IL-10 signaling blockade controls murine West Nile virus infection. PLoS Pathog. 5:e1000610.
11. Bai F, et al. 2010. A paradoxical role for neutrophils in the pathogenesis of West Nile virus J. Infect. Dis. 202:1804-1812.
12. Bai F, et al. 2007. Antiviral peptides targeting the West Nile virus envelope protein. J. Virol. 81:2047-2055.
13. Barkhash AV, et al. 2010. Variability in the 2′-5′-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. J. Infect. Dis. 202:1813-1818.
14. Bartholomay LC, et al. 2010. Pathogenomics of Culex quinquefasciatus and meta-analysis of infection responses to diverse pathogens. Science 330:88-90.
15. Beasley DW. 2011. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy 3:269-285.
16. Ben-Nathan D, Huitinga I, Lustig S, van Rooijen N, Kobiler D. 1996. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch. Virol. 141:459-469.
17. Bhuvanakantham R, Chong MK, Ng ML. 2009. Specific interaction of capsid protein and importin-alpha/beta influences West Nile virus production. Biochem. Biophys. Res. Commun. 389:63-69.
18. Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. 2011. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J. Infect. Dis. 203:75-84.
19. Bigham AW, et al. 2011. Host genetic risk factors for West Nile virus infection and disease progression. PLoS One 6:e24745. doi:10.1371/journal.pone.0024745.
20. Bowen RA, Nemeth NM. 2007. Experimental infections with West Nile virus. Curr. Opin. Infect. Dis. 20:293-297.
21. Brackney DE, Beane JE, Ebel GD. 2009. RNAi targeting of West Nile virus in mosquito midguts promotes virus diversification. PLoS Pathog. 5:e1000502. doi:10.1371/journal.ppat.1000502.
22. Brackney DE, Foy BD, Olson KE. 2008. The effects of midgut serine proteases on dengue virus type 2 infectivity of Aedes aegypti. Am. J. Trop. Med. Hyg. 79:267-274.
23. Brass AL, et al. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and Dengue virus. Cell 139: 1243-1254.
24. Brien JD, et al. 2011. Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8() T cell immune responses against West Nile virus infection. PLoS Pathog. 7:e1002230. doi:10.1371/journal.ppat.1002230.
25. Brien JD, Uhrlaub JL, Nikolich-Zugich J. 2008. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J. Immunol. 181:8568-8575.
26. Briese T, Jia XY, Huang C, Grady LJ, Lipkin WI. 1999. Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis. Lancet 354:1261-1262.
27. Brown AN, Kent KA, Bennett CJ, Bernard KA. 2007. Tissue tropism and neuroinvasion of West Nile virus do not differ for two mouse strains with different survival rates. Virology 368:422-430.
28. Busch MP, et al. 2008. Virus and antibody dynamics in acute West Nile virus infection. J. Infect. Dis. 198:984-993.
29. Calisher CH, et al. 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J. Gen. Virol. 70:37-43.
30. Calvo E, Ribeiro JM. 2006. A novel secreted endonuclease from Culex quinquefasciatus salivary glands. J. Exp. Biol. 209:2651-2659.
31. Campbell CL, et al. 2008. Aedes aegypti uses RNA interference in defense against Sindbis virus infection. BMC Microbiol. 8:47. doi:10.1186/1471-2180-8-47.
32. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. 2002. West Nile virus. Lancet Infect. Dis. 2:519-529.
33. Carlson J, Suchman E, Buchatsky L. 2006. Densoviruses for control and genetic manipulation of mosquitoes. Adv. Virus Res. 68:361-392.
34. Casrouge A, et al. 2011. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121:308-317.
35. Centers for Disease Control and Prevention. 2002. Laboratoryacquired West Nile virus infections-United States, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:1133-1135.
36. Cheng G, et al. 2010. A C-type lectin collaborates with a CD45 phosphatase homolog to facilitate West Nile virus infection of mosquitoes. Cell 142:714-725.
37. Cheng Y, King NJ, Kesson AM. 2004. Major histocompatibility complex class I (MHC-I) induction by West Nile virus: involvement of 2 signaling pathways in MHC-I up-regulation. J. Infect. Dis. 189:658-668.
38. Cheng Y, King NJ, Kesson AM. 2004. The role of tumor necrosis factor in modulating responses of murine embryo fibroblasts by flavivirus, West Nile. Virology 329:361-370.
39. Chotkowski HL, et al. 2008. West Nile virus infection of Drosophila melanogaster induces a protective RNAi response. Virology 377:197-206.
40. Chung KM, et al. 2006. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc. Natl. Acad. Sci. U. S. A. 103:19111-19116.
41. Colpitts TM, Barthel S, Wang P, Fikrig E. 2011. Dengue virus capsid protein binds core histones and inhibits nucleosome formation in human liver cells. PLoS One 6:e24365. doi:10.1371/journal.pone.0024365.
42. Colpitts TM, et al. 2011. Alterations in the Aedes aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses. PLoS Pathog. 7:e1002189. doi:10.1371/journal.ppat.1002189.
43. Colpitts TM, et al. 2011. prM-antibody renders immature West Nile virus infectious in vivo. J. Gen. Virol. 92:2281-2285.
44. Costa A, Jan E, Sarnow P, Schneider D. 2009. The Imd pathway is involved in antiviral immune responses in Drosophila. PLoS One 4:e7436. doi:10.1371/journal.pone.0007436.
45. Cross ML, Cupp EW, Enriquez FJ. 1994. Differential modulation of murine cellular immune responses by salivary gland extract of Aedes aegypti. Am. J. Trop. Med. Hyg. 51:690-696.
46. Cupp EW, et al. 2007. West Nile virus infection in mosquitoes in the mid-south USA, 2002-2005. J. Med. Entomol. 44:117-125.
47. Daffis S, Samuel MA, Keller BC, Gale M, Jr, Diamond MS. 2007. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog. 3:e106. doi:10.1371/journal.ppat.0030106.
48. Daffis S, Samuel MA, Suthar MS, Gale M, Jr, Diamond MS. 2008. Toll-like receptor 3 has a protective role against West Nile virus infection. J. Virol. 82:10349-10358.
49. Daffis S, et al. 2008. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J. Virol. 82:8465-8475.
50. Dai J, et al. 2009. Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Microbe 6:482-492.
51. da Silva Voorham JM, et al. 2012. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One 7:e29957. doi:10.1371/journal.pone.0029957.
52. Davis CW, et al. 2006. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 80:1290-1301.
53. Demento SL, et al. 2010. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J. Immunol. 185:2989-2997.
54. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. 2003. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77:2578-2586.
55. Diamond MS. 2005. Development of effective therapies against West Nile virus infection. Expert Rev. Anti Infect. Ther. 3:931-944.
56. Douglas MW, Kesson AM, King NJ. 1994. CTL recognition of West Nile virus-infected fibroblasts is cell cycle dependent and is associated with virus-induced increases in class I MHC antigen expression. Immunology 82:561-570.
57. Edwards JF, Higgs S, Beaty BJ. 1998. Mosquito feeding-induced enhancement of Cache Valley virus (Bunyaviridae) infection in mice. J. Med. Entomol. 35:261-265.
58. Elshuber S, Allison SL, Heinz FX, Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 84:183-191.
59. Farajollahi A, Nelder MP. 2009. Changes in Aedes albopictus (Diptera: Culicidae) populations in New Jersey and implications for arbovirus transmission. J. Med. Entomol. 46:1220-1224.
60. Franz AW, et al. 2006. Engineering RNA interference-based resistance to dengue virus type 2 in genetically modified Aedes aegypti. Proc. Natl. Acad. Sci. U. S. A. 103:4198-4203.
61. Fredericksen BL, Gale M, Jr. 2006. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. J. Virol. 80: 2913-2923.
62. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M, Jr. 2008. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J. Virol. 82:609-616.
63. Fredericksen BL, Smith M, Katze MG, Shi PY, Gale M, Jr. 2004. The host response to West Nile Virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78: 7737-7747.
64. Friebe P, Harris E. 2010. Interplay of RNA elements in the dengue virus 5′ and 3′ ends required for viral RNA replication. J. Virol. 84:6103-6118.
65. Fu G, et al. 2007. Female-specific insect lethality engineered using alternative splicing. Nat. Biotechnol. 25:353-357.
66. Fu G, et al. 2010. Female-specific flightless phenotype for mosquito control. Proc. Natl. Acad. Sci. U. S. A. 107:4550-4554.
67. Gibney KB, et al. 2011. West Nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease. J. Infect. Dis. 203:344-347.
68. Gilfoy FD, Mason PW. 2007. West Nile virus-induced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR. J. Virol. 81:11148-11158.
69. Girard YA, Popov V, Wen J, Han V, Higgs S. 2005. Ultrastructural study of West Nile virus pathogenesis in Culex pipiens quinquefasciatus (Diptera: Culicidae). J. Med. Entomol. 42:429-444.
70. Glass WG, et al. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203:35-40.
71. Goodell JR, Puig-Basagoiti F, Forshey BM, Shi PY, Ferguson DM. 2006. Identification of compounds with anti-West Nile virus activity. J. Med. Chem. 49:2127-2137.
72. Gould HL, et al. 2005. Protective and therapeutic capacity of human single chain Fv-Fc fusion proteins against West Nile virus. J. Virol. 79: 14606-14613.
73. Gould LH, Fikrig E. 2004. West Nile virus: a growing concern? J. Clin. Invest. 113:1102-1107.
74. Granwehr BP, et al. 2004. West Nile virus: where are we now? Lancet Infect. Dis. 4:547-556.
75. Gu B, et al. 2006. Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. Antiviral Res. 70:39-50.
76. Gubler DJ. 2007. The continuing spread of West Nile virus in the western hemisphere. Clin. Infect. Dis. 45:1039-1046.
77. Guo X, et al. 2009. Inhibition of neutrophil function by two tick salivary proteins. Infect. Immun. 77:2320-2329.
78. Hamdan A, et al. 2002. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl. Infect. Dis. 4:160-162.
79. Hamer GL, et al. 2008. Culex pipiens (Diptera: Culicidae): a bridge vector of West Nile virus to humans. J. Med. Entomol. 45:125-128.
80. Hamer GL, et al. 2009. Host selection by Culex pipiens mosquitoes and West Nile virus amplification. Am. J. Trop. Med. Hyg. 80:268-278.
81. Hayes EB, O'Leary DR. 2004. West Nile virus infection: a pediatric perspective. Pediatrics 113:1375-1381.
82. Hoffmann AA, et al. 2011. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 476:454-457.
83. Holick J, Kyle A, Ferraro W, Delaney RR, Iwaseczko M. 2002. Discovery of Aedes albopictus infected with west nile virus in southeastern Pennsylvania. J. Am. Mosq. Control Assoc. 18:131.
84. Hudson A, Bowman L, Orr CW. 1960. Effects of absence of saliva on blood feeding by mosquitoes. Science 131:1730-1731.
85. Iwamoto M, et al. 2003. Transmission of West Nile virus from an organ donor to four transplant recipients. N. Engl. J. Med. 348:2196-2203.
86. Jarman RV, Morgan PN, Duffy CE. 1968. Persistence of West Nile virus in L-929 mouse fibroblasts. Proc. Soc. Exp. Biol. Med. 129:633-637.
87. Kajaste-Rudnitski A, et al. 2006. The 2′,5′-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells. J. Biol. Chem. 281:4624-4637.
88. Kalil AC, et al. 2005. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin. Infect. Dis. 40:764-766.
89. Kato N, et al. 2008. Evaluation of the function of a type I peritrophic matrix as a physical barrier for midgut epithelium invasion by mosquitoborne pathogens in Aedes aegypti. Vector Borne Zoonotic Dis. 8:701-712.
90. Keene KM, et al. 2004. RNA interference acts as a natural antiviral response to O'nyong-nyong virus (Alphavirus; Togaviridae) infection of Anopheles gambiae. Proc. Natl. Acad. Sci. U. S. A. 101:17240-17245.
91. Kent R, Juliusson L, Weissmann M, Evans S, Komar N. 2009. Seasonal blood-feeding behavior of Culex tarsalis (Diptera: Culicidae) in Weld County, Colorado, 2007. J. Med. Entomol. 46:380-390.
92. Khromykh AA, Meka H, Guyatt KJ, Westaway EG. 2001. Essential role of cyclization sequences in flavivirus RNA replication. J. Virol. 75:6719-6728.
93. Kilpatrick AM. 2011. Globalization, land use, and the invasion of West Nile virus. Science 334:323-327.
94. Kilpatrick AM, Daszak P, Jones MJ, Marra PP, Kramer LD. 2006. Host heterogeneity dominates West Nile virus transmission. Proc. Biol. Sci. 273:2327-2333.
95. Kilpatrick AM, et al. 2005. West Nile virus risk assessment and the bridge vector paradigm. Emerg. Infect. Dis. 11:425-429.
96. Kilpatrick AM, Kramer LD, Jones MJ, Marra PP, Daszak P. 2006. West Nile virus epidemics in North America are driven by shifts in mosquito feeding behavior. PLoS Biol. 4:e82. doi:10.1371/journal.pbio.0040082.
97. King NJ, et al. 2007. Immunopathology of flavivirus infections. Immunol. Cell Biol. 85:33-42.
98. Klein RS, et al. 2005. Neuronal CXCL10 directs CD8 T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79:11457-11466.
99. Kokoza V, et al. 2000. Engineering blood meal-activated systemic immunity in the yellow fever mosquito, Aedes aegypti. Proc. Natl. Acad. Sci. U. S. A. 97:9144-9149.
100. Komar N, et al. 2003. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg. Infect. Dis. 9:311-322.
101. Kong KF, et al. 2008. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. J. Virol. 82:7613-7623.
102. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. 1998. Phylogeny of the genus Flavivirus. J. Virol. 72:73-83.
103. Kurane I, Janus J, Ennis FA. 1992. Dengue virus infection of human skin fibroblasts in vitro production of IFN-beta, IL-6 and GM-CSF. Arch. Virol. 124:21-30.
104. Kusne S, Smilack J. 2005. Transmission of West Nile virus by organ transplantation. Liver Transpl. 11:239-241.
105. Lanciotti RS, et al. 1999. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286: 2333-2337.
106. Lanteri MC, et al. 2008. Comprehensive analysis of West Nile virusspecific T cell responses in humans. J. Infect. Dis. 197:1296-1306.
107. Lanteri MC, et al. 2011. Association between HLA class I and class II alleles and the outcome of West Nile virus infection: an exploratory study. PLoS One 6:e22948. doi:10.1371/journal.pone.0022948.
108. Lanteri MC, et al. 2009. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J. Clin. Invest. 119:3266-3277.
109. Lazear HM, Pinto AK, Vogt MR, Gale M, Jr, Diamond MS. 2011. Beta interferon controls West Nile virus infection and pathogenesis in mice. J. Virol. 85:7186-7194.
110. Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78:8271-8280.
111. Li J, et al. 2003. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann. Neurol. 53:703-710.
112. Lim JK, et al. 2009. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 5:e1000321. doi: 10.1371/journal.ppat.1000321.
113. Lim JK, et al. 2008. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a metaanalysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197:262-265.
114. Lim JK, et al. 2010. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J. Infect. Dis. 201:178-185.
115. Lim JK, et al. 2011. Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J. Immunol. 186:471-478.
116. Lim PY, Behr MJ, Chadwick CM, Shi PY, Bernard KA. 2011. Keratinocytes are cell targets of West Nile virus in vivo. J. Virol. 85:5197-5201.
117. Lin CW, et al. 2008. Interferon antagonist function of Japanese encephalitis virus NS4A and its interaction with DEAD-box RNA helicase DDX42. Virus Res. 137:49-55.
118. Lindenbach BD, Rice CM. 2003. Molecular biology of flaviviruses. Adv. Virus Res. 59:23-61.
119. Lindenbach DR CM. 2001. Flaviviridae: the viruses and their replication, p 991-1041. In Knipe DM, Howley PM (ed), Fields virology, 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
120. Lindsey NP, et al. 2007. West Nile virus activity-United States, 2006. JAMA 298:619-621.
121. Lindsey NP, Sejvar JJ, Bode AV, Pape WJ, Campbell GL. 2012. Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003. Vector Borne Zoonotic Dis. 12:230-235.
122. Liu WJ, Chen HB, Wang XJ, Huang H, Khromykh AA. 2004. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. J. Virol. 78:12225-12235.
123. Liu WJ, et al. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J. Virol. 80:2396-2404.
124. Loeb M, Eskandarian S, Rupp M. 2011. Genetic variants and susceptibility to neurological complications following West Nile virus infection. J. Infect. Dis. 204:1031-1037.
125. Luplertlop N, et al. 2011. Induction of a peptide with activity against a broad spectrum of pathogens in the Aedes aegypti salivary gland, following infection with dengue virus. PLoS Pathog. 7:e1001252. doi:10.1371/ journal.ppat.1001252.
126. Marfin AA, Gubler DJ. 2001. West Nile encephalitis: an emerging disease in the United States. Clin. Infect. Dis. 33:1713-1719.
127. McGee CE, et al. 2010. Infection, dissemination, and transmission of a West Nile virus green fluorescent protein infectious clone by Culex pipiens quinquefasciatus mosquitoes. Vector Borne Zoonotic Dis. 10:267-274.
128. McMeniman CJ, et al. 2009. Stable introduction of a life-shortening Wolbachia infection into the mosquito Aedes aegypti. Science 323:141-144.
129. Medlock J, Luz PM, Struchiner CJ, Galvani AP. 2009. The impact of transgenic mosquitoes on dengue virulence to humans and mosquitoes. Am. Nat. 174:565-577.
130. Mehlhop E, Diamond MS. 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203:1371-1381.
131. Mehlhop E, et al. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6:381-391.
132. Mehlhop E, et al. 2005. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J. Virol. 79:7466-7477.
133. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319.
134. Moesker B, Rodenhuis-Zybert IA, Meijerhof T, Wilschut J, Smit JM. 2010. Characterization of the functional requirements of West Nile virus membrane fusion. J. Gen. Virol. 91:389-393.
135. Molaei G, Andreadis TG, Armstrong PM, Anderson JF, Vossbrinck CR. 2006. Host feeding patterns of Culex mosquitoes and West Nile virus transmission, northeastern United States. Emerg. Infect. Dis. 12:468-474.
136. Molina-Cruz A, et al. 2005. Effect of mosquito midgut trypsin activity on dengue-2 virus infection and dissemination in Aedes aegypti. Am. J. Trop. Med. Hyg. 72:631-637.
137. Munoz-Jordan JL, et al. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79:8004-8013.
138. Murray K, et al. 2006. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol. Infect. 134:1325-1332.
139. Murray K, et al. 2010. Persistent infection with West Nile virus years after initial infection. J. Infect. Dis. 201:2-4.
140. Murray KO, Walker C, Gould E. 2011. The virology, epidemiology, and clinical impact of West Nile virus: a decade of advancements in research since its introduction into the Western Hemisphere. Epidemiol. Infect. 139:807-817.
141. Nash D, et al. 2001. The outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344:1807-1814.
142. Oliphant T, et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
143. Olson KE, et al. 2002. Developing arbovirus resistance in mosquitoes. Insect Biochem. Mol. Biol. 32:1333-1343.
144. Olson KE, et al. 1996. Genetically engineered resistance to dengue-2 virus transmission in mosquitoes. Science 272:884-886.
145. Papa A, Danis K, Athanasiadou A, Delianidou M, Panagiotopoulos T. 2011. Persistence of West Nile virus immunoglobulin M antibodies, Greece. J. Med. Virol. 83:1857-1860.
146. Parsons R, et al. 2008. The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8 T cell epitopes. J. Immunol. 181:1563-1572.
147. Pesko K, Mores CN. 2009. Effect of sequential exposure on infection and dissemination rates for West Nile and St. Louis encephalitis viruses in Culex quinquefasciatus. Vector Borne Zoonotic Dis. 9:281-286.
148. Petersen LR, Marfin AA. 2002. West Nile virus: a primer for the clinician. Ann. Intern. Med. 137:173-179.
149. Piazza P, et al. 2010. Surface phenotype and functionality of WNV specific T cells differ with age and disease severity. PLoS One 5:e15343. doi:10.1371/journal.pone.0015343.
150. Pinto AK, et al. 2011. A temporal role of type I interferon signaling in CD8 T cell maturation during acute West Nile virus infection. PLoS Pathog. 7:e1002407. doi:10.1371/journal.ppat.1002407.
151. Pogodina VV, et al. 1983. Study on West Nile virus persistence in monkeys. Arch. Virol. 75:71-86.
152. Prince HE, Lape-Nixon M, Yeh C, Tobler LH, Busch MP. 2008. Persistence of antibodies to West Nile virus nonstructural protein 5. J. Clin. Virol. 43:102-106.
153. Puig-Basagoiti F, et al. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50:1320-1329.
154. Qian F, et al. 2011. Impaired interferon signaling in dendritic cells from older donors infected in vitro with West Nile virus. J. Infect. Dis. 203: 1415-1424.
155. Ramamoorthi N, et al. 2005. The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 436:573-577.
156. Ramirez JL, Dimopoulos G. 2010. The Toll immune signaling pathway control conserved anti-dengue defenses across diverse Ae. aegypti strains and against multiple dengue virus serotypes. Dev. Comp. Immunol. 34: 625-629.
157. Rappole JH, Derrickson SR, Hubalek Z. 2000. Migratory birds and spread of West Nile virus in the Western Hemisphere. Emerg. Infect. Dis. 6:319-328.
158. Reisen WK, Fang Y, Martinez VM. 2005. Avian host and mosquito (Diptera: Culicidae) vector competence determine the efficiency of West Nile and St. Louis encephalitis virus transmission. J. Med. Entomol. 42: 367-375.
159. Reisen WK, Fang Y, Martinez VM. 2006. Vector competence of Culiseta incidens and Culex thriambus for West Nile virus. J. Am. Mosq. Control Assoc. 22:662-665.
160. Rezepova AI, Kuz'Mina SV, Kulikova KS, Unanov SS. 1971. Cultivation of various arboviruses in new transplantable lines of mouse fibroblasts. Vopr. Virusol. 16:704-707.
161. Ribeiro JM. 2000. Blood-feeding in mosquitoes: probing time and salivary gland anti-haemostatic activities in representatives of three genera (Aedes, Anopheles, Culex). Med. Vet. Entomol. 14:142-148.
162. Ribeiro JM, et al. 2007. An annotated catalogue of salivary gland transcripts in the adult female mosquito, Aedes aegypti. BMC Genomics 8:6. doi:10.1186/1471-2164-8-6.
163. Ribeiro JM, Charlab R, Rowton ED, Cupp EW. 2000. Simulium vittatum (Diptera: Simuliidae) and Lutzomyia longipalpis (Diptera: Psychodidae) salivary gland hyaluronidase activity. J. Med. Entomol. 37: 743-747.
164. Ribeiro JM, Charlab R, Valenzuela JG. 2001. The salivary adenosine deaminase activity of the mosquitoes Culex quinquefasciatus and Aedes aegypti. J. Exp. Biol. 204:2001-2010.
165. Ribeiro JM, Francischetti IM. 2001. Platelet-activating-factor-hydrolyzing phospholipase C in the salivary glands and saliva of the mosquito Culex quinquefasciatus. J. Exp. Biol. 204:3887-3894.
166. Ribeiro JM, Rossignol PA, Spielman A. 1985. Aedes aegypti: model for blood finding strategy and prediction of parasite manipulation. Exp. Parasitol. 60:118-132.
167. Ribeiro JM, Rossignol PA, Spielman A. 1984. Role of mosquito saliva in blood vessel location. J. Exp. Biol. 108:1-7.
168. Ribeiro JM, Valenzuela JG. 2003. The salivary purine nucleosidase of the mosquito, Aedes aegypti. Insect Biochem. Mol. Biol. 33:13-22.
169. Rice CM. 1996. Flaviviradae: the viruses and their replication, p 931-959. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, PA.
170. Richards SL, Anderson SL, Lord CC, Smartt CT, Tabachnick WJ. 2012. Relationships between infection, dissemination, and transmission of West Nile virus RNA in Culex pipiens quinquefasciatus (Diptera: Culicidae). J. Med. Entomol. 49:132-142.
171. Rios JJ, et al. 2010. OAS1 polymorphisms are associated with susceptibility to West Nile encephalitis in horses. PLoS One 5:e10537. doi: 10.1371/journal.pone.0010537.
172. Rios M, et al. 2006. Monocytes-macrophages are a potential target in human infection with West Nile virus through blood transfusion. Transfusion 46:659-667.
173. Rocha AC, Braga EM, Araujo MS, Franklin BS, Pimenta PF. 2004. Effect of the Aedes fluviatilis saliva on the development of Plasmodium gallinaceum infection in Gallus (gallus) domesticus. Mem. Inst. Oswaldo Cruz 99:709-715.
174. Rodenhuis-Zybert IA, et al. 2010. Immature dengue virus: a veiled pathogen? PLoS Pathog. 6:e1000718. doi:10.1371/journal.ppat.1000718.
175. Roehrig JT, et al. 2003. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed West Nile virus encephalitis cases. Emerg. Infect. Dis. 9:376-379.
176. Samuel MA, Diamond MS. 2005. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79:13350-13361.
177. Samuel MA, et al. 2006. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 80:7009-7019.
178. Sangiambut S, et al. 2008. Multiple regions in dengue virus capsid protein contribute to nuclear localization during virus infection. J. Gen. Virol. 89:1254-1264.
179. Sardelis MR, Turell MJ, O'Guinn ML, Andre RG, Roberts DR. 2002. Vector competence of three North American strains of Aedes albopictus for West Nile virus. J. Am. Mosq. Control Assoc. 18:284-289.
180. Scherbik SV, Stockman BM, Brinton MA. 2007. Differential expression of interferon (IFN) regulatory factors and IFN-stimulated genes at early times after West Nile virus infection of mouse embryo fibroblasts. J. Virol. 81:12005-12018.
181. Schneider BS, Higgs S. 2008. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans. R. Soc. Trop. Med. Hyg. 102:400-408.
182. Schneider BS, et al. 2007. Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection. PLoS One 2:e1171. doi:10.1371/journal.pone.0001171.
183. Schneider BS, et al. 2010. Aedes aegypti saliva alters leukocyte recruitment and cytokine signaling by antigen-presenting cells during West Nile virus infection. PLoS One 5:e11704. doi:10.1371/journal.pone.0011704.
184. Schneider BS, et al. 2006. Potentiation of West Nile encephalitis by mosquito feeding. Viral Immunol. 19:74-82.
185. Schneider BS, Soong L, Zeidner NS, Higgs S. 2004. Aedes aegypti salivary gland extracts modulate anti-viral and TH1/TH2 cytokine responses to sindbis virus infection. Viral Immunol. 17:565-573.
186. Sejvar JJ, et al. 2003. Neurologic manifestations and outcome of West Nile virus infection. JAMA 290:511-515.
187. Sejvar JJ, Lindsey NP, Campbell GL. 2011. Primary causes of death in reported cases of fatal West Nile Fever, United States, 2002-2006. Vector Borne Zoonotic Dis. 11:161-164.
188. Sessions OM, et al. 2009. Discovery of insect and human dengue virus host factors. Nature 458:1047-1050.
189. Shao L, Devenport M, Jacobs-Lorena M. 2001. The peritrophic matrix of hematophagous insects. Arch. Insect Biochem. Physiol. 47:119-125.
190. Shen J, Devery JM, King NJ. 1995. Early induction of interferonindependent virus-specific ICAM-1 (CD54) expression by flavivirus in quiescent but not proliferating fibroblasts-implications for virus-host interactions. Virology 208:437-449.
191. Shi PY, Brinton MA, Veal JM, Zhong YY, Wilson WD. 1996. Evidence for the existence of a pseudoknot structure at the 3′ terminus of the flavivirus genomic RNA. Biochemistry 35:4222-4230.
192. Shrestha B, Diamond MS. 2004. Role of CD8 T cells in control of West Nile virus infection. J. Virol. 78:8312-8321.
193. Shrestha B, Pinto AK, Green S, Bosch I, Diamond MS. 2012. CD8 T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. J. Virol. 86:8937-8948.
194. Shrestha B, et al. 2006. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80:5338-5348.
195. Shrestha B, Zhang B, Purtha WE, Klein RS, Diamond MS. 2008. Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system. J. Virol. 82:8956-8964.
196. Siddharthan V, et al. 2009. Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation. J. Virol. 83:4251-4261.
197. Sim S, Dimopoulos G. 2010. Dengue virus inhibits immune responses in Aedes aegypti cells. PLoS One 5:e10678. doi:10.1371/journal.pone.0010678.
198. Sitati E, McCandless EE, Klein RS, Diamond MS. 2007. CD40-CD40 ligand interactions promote trafficking of CD8 T cells into the brain and protection against West Nile virus encephalitis. J. Virol. 81:9801-9811.
199. Sitati EM, Diamond MS. 2006. CD4 T-cell responses are required for clearance of West Nile virus from the central nervous system. J. Virol. 80:12060-12069.
200. Smartt CT, Richards SL, Anderson SL, Erickson JS. 2009. West Nile virus infection alters midgut gene expression in Culex pipiens quinquefasciatus Say (Diptera: Culicidae). Am. J. Trop. Med. Hyg. 81:258-263.
201. Souza-Neto JA, Sim S, Dimopoulos G. 2009. An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense. Proc. Natl. Acad. Sci. U. S. A. 106:17841-17846.
202. Stracker TH, Thompson S, Grossman GL, Riehle MA, Brown MR. 2002. Characterization of the AeaHP gene and its expression in the mosquito Aedes aegypti (Diptera: Culicidae). J. Med. Entomol. 39:331-342.
203. Styer LM, Bernard KA, Kramer LD. 2006. Enhanced early West Nile virus infection in young chickens infected by mosquito bite: effect of viral dose. Am. J. Trop. Med. Hyg. 75:337-345.
204. Styer LM, et al. 2007. Mosquitoes inoculate high doses of West Nile virus as they probe and feed on live hosts. PLoS Pathog. 3:1262-1270. doi: 10.1371/journal.ppat.0030132.
205. Styer LM, et al. 2011. Mosquito saliva causes enhancement of West Nile virus infection in mice. J. Virol. 85:1517-1527.
206. Sultana H, et al. 2009. Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J. Immunol. 183:650-660.
207. Suthar MS, et al. 2010. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog. 6:e1000757. doi:10.1371/journal.ppat.1000757.
208. Suthar MS, et al. 2012. The RIG-I-like receptor LGP2 controls CD8 T cell survival and fitness. Immunity 37:235-248.
209. Szretter KJ, et al. 2010. The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. J. Virol. 84:12125-12138.
210. Szretter KJ, et al. 2009. The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. J. Virol. 83: 9329-9338.
211. Tassaneetrithep B, et al. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197:823-829.
212. Tempelis CH, Francy DB, Hayes RO, Lofy MF. 1967. Variations in feeding patterns of seven culicine mosquitoes on vertebrate hosts in Weld and Larimer Counties, Colorado. Am. J. Trop. Med. Hyg. 16: 111-119.
213. Tesh RB, et al. 2005. Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J. Infect. Dis. 192:287-295.
214. Thomas DD, Donnelly CA, Wood RJ, Alphey LS. 2000. Insect population control using a dominant, repressible, lethal genetic system. Science 287:2474-2476.
215. Thoma-Uszynski S, et al. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291:1544-1547.
216. Tiawsirisup S, Platt KB, Evans RB, Rowley WA. 2005. A comparision of West Nile Virus transmission by Ochlerotatus trivittatus (COQ.), Culex pipiens (L.), and Aedes albopictus (Skuse). Vector Borne Zoonotic Dis. 5:40-47.
217. Tobler LH, et al. 2008. Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virusinfected blood donors. J. Infect. Dis. 198:979-983.
218. Town T, et al. 2009. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 30:242-253.
219. Unlu I, Mackay AJ, Roy A, Yates MM, Foil LD. 2010. Evidence of vertical transmission of West Nile virus in field-collected mosquitoes. J. Vector Ecol. 35:95-99.
220. Vaidyanathan R, Scott TW. 2006. Apoptosis in mosquito midgut epithelia associated with West Nile virus infection. Apoptosis 11:1643-1651.
221. Vanlandingham DL, et al. 2007. Relative susceptibilties of South Texas mosquitoes to infection with West Nile virus. Am. J. Trop. Med. Hyg. 77:925-928.
222. Vitek CJ, Richards SL, Mores CN, Day JF, Lord CC. 2008. Arbovirus transmission by Culex nigripalpus in Florida, 2005. J. Med. Entomol. 45:483-493.
223. Volfova V, Hostomska J, Cerny M, Votypka J, Volf P. 2008. Hyaluronidase of bloodsucking insects and its enhancing effect on leishmania infection in mice. PLoS Negl. Trop. Dis. 2:e294.
224. Wanasen N, Nussenzveig RH, Champagne DE, Soong L, Higgs S. 2004. Differential modulation of murine host immune response by salivary gland extracts from the mosquitoes Aedes aegypti and Culex quinquefasciatus. Med. Vet. Entomol. 18:191-199.
225. Wang P. IL-22 signaling contributes to West Nile encephalitis pathogenesis. PLoS One, in press.
226. Wang P, et al. 2010. Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I. Nat. Immunol. 11:912-919.
227. Wang P, et al. 2008. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J. Virol. 82:8978-8985.
228. Wang S, et al. 2008. Drak2 contributes to West Nile virus entry into the brain and lethal encephalitis. J. Immunol. 181:2084-2091.
229. Wang T, et al. 2003. IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection. J. Immunol. 171:2524-2531.
230. Wang T, et al. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10:1366-1373.
231. Wasserman HA, Singh S, Champagne DE. 2004. Saliva of the Yellow Fever mosquito, Aedes aegypti, modulates murine lymphocyte function. Parasite Immunol. 26:295-306.
232. Weiss D, et al. 2001. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg. Infect. Dis. 7:654-658.
233. Welte T, et al. 2009. Toll-like receptor 7-induced immune response to cutaneous West Nile virus infection. J. Gen. Virol. 90:2660-2668.
234. Westaway EG, Mackenzie JM, Khromykh AA. 2002. Replication and gene function in Kunjin virus. Curr. Top. Microbiol. Immunol. 267:323-351.
235. Whiteman MC, et al. 2010. Development and characterization of nonglycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 28:1075-1083.
236. Yakub I, et al. 2005. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J. Infect. Dis. 192:1741-1748.
237. Zhang B, Chan YK, Lu B, Diamond MS, Klein RS. 2008. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J. Immunol. 180: 2641-2649.
238. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG. 2007. Structure of immature West Nile virus. J. Virol. 81:6141-6145.
239. Zou S, Foster GA, Dodd RY, Petersen LR, Stramer SL. 2010. West Nile fever characteristics among viremic persons identified through blood donor screening. J. Infect. Dis. 202:1354-1361.
240. Zybert IA, van der Ende-Metselaar H, Wilschut J, Smit JM. 2008. Functional importance of dengue virus maturation: infectious properties of immature virions. J. Gen. Virol. 89:3047-3051.